Gilead: The Healer and the Profiteer

Discover how Gilead Sciences revolutionized HIV and Hepatitis C treatment while becoming the center of a global firestorm over drug pricing.[INTRO]ALEX: In 2013, a pharmaceutical company released a pill that could cure Hepatitis C in twelve weeks, basically performing a medical miracle. But they priced it at exactly one thousand dollars per pill.JORDAN: Wait, a thousand dollars for a single pill? That’s eighty-four thousand dollars for the full treatment. Did people actually pay that?ALEX: Many couldn't, and that’s the paradox of Gilead Sciences. They’ve saved millions of lives from HIV and Hep-C, but they also became the ultimate symbol of pharmaceutical greed.JORDAN: So they essentially found the cure for a plague and then put it behind a velvet rope. I think we need to look into how they got that kind of power.[CHAPTER 1 - Origin]ALEX: It all starts in 1987 with a 29-year-old doctor named Michael Riordan. He had a Harvard MBA and a crazy idea to use 'antisense' technology to block genes and stop viruses in their tracks.JORDAN: A 29-year-old running a biotech firm? That sounds like the ultimate Silicon Valley 'move fast and break things' energy.ALEX: Exactly, but the high-risk science didn't actually work at first. The breakthrough happened when Riordan hired two chemistry experts, John Martin and Norbert Bischofberger, who shifted the focus to nucleotide analogs.JORDAN: Okay, translate that for me. What are we actually talking about?ALEX: Think of them as 'decoy' building blocks. When a virus tries to replicate its DNA, it grabs these fake blocks instead of real ones, and the whole process just grinds to a halt.JORDAN: So they're basically feeding the virus bad instructions. How did they pay for all this research before they had a product?ALEX: They went public in 1992, raising 86 million dollars, but their real 'lottery ticket' was a drug they invented called Tamiflu. They licensed it to Roche, and when the swine flu pandemic hit years later, the royalties gave Gilead a multi-billion dollar war chest.[CHAPTER 2 - Core Story]ALEX: By the early 2000s, Gilead turned its attention to the HIV crisis. At the time, HIV patients had to take a 'cocktail' of dozens of pills every single day, which was a logistical nightmare.JORDAN: I remember that—if you missed even one dose, the virus could mutate and become resistant. It was a high-stakes balancing act.ALEX: Gilead fixed that. In 2004, they launched Truvada, which combined multiple medicines into one. Then in 2006, they released Atripla—the first-ever once-a-day single pill for HIV.JORDAN: That’s a total game-changer for quality of life. They basically owned the HIV market at that point, right?ALEX: They did. But their biggest gamble was still coming. In 2011, Gilead spent 11 billion dollars to buy a small company called Pharmasset just to get their hands on one experimental Hep-C drug.JORDAN: Eleven billion for one drug that wasn't even on the market yet? Wall Street must have hated that.ALEX: Analysts called them crazy, until the drug, Sovaldi, was approved. It didn't just manage Hepatitis C; it cured it in 90% of patients with almost no side effects.JORDAN: That brings us back to the thousand-dollar pill. If you have the only cure for a deadly disease, you can basically charge whatever you want.ALEX: And they did. They followed up with Harvoni, which cost 94,000 dollars per course. The revenue was so massive it catapulted Gilead into the top tier of big pharma, but it also triggered a 18-month Senate investigation.JORDAN: Let me guess: the Senate found they were maximizing profits over patient access?ALEX: Precisely. The report said Gilead picked the price specifically to see how much the market could bear, regardless of the fact that it was bankrupting state Medicaid budgets.[CHAPTER 3 - Why It Matters]JORDAN: So, where is Gilead now? Are they still just the 'antiviral' company?ALEX: They’re trying to pivot. As they’ve cured more Hep-C patients, their customer base for that drug is actually shrinking—which is the weird irony of curing a disease.JORDAN: Right, a cured patient isn't a repeat customer. So what's the next act?ALEX: They’re betting big on cancer. They’ve spent over 30 billion dollars acquiring companies like Kite Pharma and Immunomedics to get into cell therapy and breast cancer treatments.JORDAN: And I'm assuming they're still in the headlines for other things?ALEX: Always. They developed Remdesivir for COVID-19, which was the first drug approved for the pandemic. But even then, they faced lawsuits over 'evergreening'—essentially holding back safer versions of their HIV drugs just to keep their older patents profitable for longer.JORDAN: It sounds like they are the ultimate example of the tension in modern medicine: we need these companies to take huge risks to find cures, but once they find them, we can't afford to pay the bill.[OUTRO]JORDAN: What’s the one thing to remember about Gilead Sciences?ALEX: Gilead proved that a single-pill cure is scientifically possible, but they also proved that the price of life-saving innovation is often higher than the system can handle.JORDAN: That’s Wikipodia — every story, on demand. Search your next topic at wikipodia.ai